Red Flags Detected

• ⚠ Material Weaknesses (new) — The company disclosed material weaknesses in internal control over financial reporting for fiscal years 2024 and 2025, including ineffective controls around the financial statement close process and information system controls.
• ⚠ Thrombosis (new) — Serious adverse events of thrombosis, including a proximal deep vein thrombosis and a subsegmental pulmonary embolism, were identified in the development of sutacimig, the company's lead product candidate.
• ⚠ Dependence On Two Product Candidates (new) — The company is heavily dependent on the success of sutacimig and HMB-002, its only clinical-stage product candidates, and failure of either would materially harm the business.
• ⚠ License Agreements With Novo Nordisk and Genmab (new) — The company's lead product candidate sutacimig is dependent on licenses from Novo Nordisk and Genmab, and termination of either agreement could lead to loss of rights to develop and commercialize sutacimig.